Exact Sciences
About Exact Sciences
Exact Sciences is a molecular diagnostics company dedicated to the early detection and prevention of cancer, as well as guiding treatment decisions. The company is best known for its non-invasive colorectal cancer screening test, Cologuard, which analyzes stool samples for DNA markers and occult hemoglobin to assess a patient’s risk of colorectal cancer. Cologuard was the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage, revolutionizing colorectal cancer screening.
Beyond colorectal cancer screening, Exact Sciences offers a range of precision oncology tests, including the Oncotype DX portfolio, which provides genomic insights to inform prognosis and guide treatment decisions for various cancers, particularly breast cancer. The company’s strategy involves building a comprehensive cancer platform that spans screening, minimal residual disease detection, and precision oncology, with a pipeline that includes next-generation colorectal screening and blood-based multi-cancer early detection efforts. Exact Sciences collaborates with leading institutions and healthcare providers to distribute its products and is committed to addressing health equity by improving access to cancer screening and education in underserved communities.
Focus Areas
Business Intelligence
| Key Investors | Back Bay Group, Bayview Investors, CB Health Ventures, Excel Venture Management, Great Point Partners, Petrillo Capital, Bank of America [3, 25] |
| Partnerships | Mayo Clinic, Johns Hopkins University, TGen (part of City of Hope), Flatiron Health, Broad Institute of MIT and Harvard, Baylor Scott & White, Humana, Wisconsin Clinical Lab Network, Jefferson Health [2, 20, 27, 29, 33] |
| Acquisitions | Paradigm Diagnostics (2020), Viomics (2020), Thrive Earlier Detection Corp. (2020), Prevention Genetics (2022), Resolution Bioscience (2023), Sampleminded (2017), Biomatrica (2018), Ashion Analytics (2021) [1, 2, 4, 14] |
| Technology | ExactNexus technology platform (unified clinical experience, connects health systems, providers, payers, AI-generated insights), proprietary stool DNA isolation, DNA stability technology, QuARTS technology (Quantitative Allele-specific Real-time Target and Signal Amplification) for DNA biomarker detection [7, 8, 31] |
| FDA Clearances | Unknown (Cologuard received premarket approval from the FDA in 2014) [1] cleared products (estimated) |
What Physicians Need to Know
Exact Sciences' tests offer actionable genomic insights to guide treatment decisions across the cancer care continuum. The Oncotype DX Breast Recurrence Scoreu00ae test is a standard of care for predicting chemotherapy benefit in breast cancer. [1, 14, 15, 26] The Oncodetectu2122 MRD test can detect cancer recurrence earlier than traditional imaging, enabling timely intervention. [4, 5, 6] The OncoExTrau00ae test provides comprehensive genomic profiling to identify actionable variants for advanced solid tumors, aiding in targeted therapy and clinical trial selection. [11, 16, 19] Their ExactNexusu2122 technology platform aims to streamline workflows and integrate solutions into existing health system processes, making ordering and result access easier. [12, 21] Exact Sciences emphasizes informed decision-making, offering various screening options and providing clear information to help physicians and patients choose the best path. [8, 32]
Exact Sciences utilizes its ExactNexusu2122 technology platform to create a unified clinical experience, connecting health systems, providers, payers, and patients. [12, 21] This platform supports easy ordering via the Exact Sciences Provider Hub, EpicCare Link, electronic interfaces, and fax. [21] They are equipped to integrate solutions into existing workflows, aiming to streamline genomic cancer testing and optimize and automate workflows for clinicians and staff. [12, 21] Their bioinformatics infrastructure leverages AWS HealthOmics for efficient processing of large genomic datasets. [20]
What the Web Says
Exact Sciences is a cancer diagnostics company known for its Cologuard test. Reviews for the company and its product are mixed. While Cologuard is praised for its convenience as an at-home screening option, concerns exist regarding its accuracy, particularly its false positive and false negative rates for polyps, and potential insurance billing issues. As an employer, Exact Sciences is seen as a fast-growing company with competitive pay and benefits, but some employees report issues with management, communication, and work-life balance.
Overall: MixedStrengths
- Cologuard offers a convenient and non-invasive at-home screening option for colon cancer.
- Exact Sciences has a motivating mission to combat cancer and a collaborative team environment.
- The company offers competitive pay and benefits, including potentially free medical care and good time-off packages.
- Some employees report a positive work-life balance.
- Opportunities for professional development exist, especially in the diagnostic healthcare space.
- Cologuard is considered a reasonable alternative for low-risk individuals who cannot undergo a colonoscopy.
Limitations
- Cologuard has a notable false positive rate, leading to unnecessary colonoscopies and potential surprise bills.
- Cologuard is less effective at detecting pre-cancerous polyps compared to a colonoscopy.
- Some employees report negative experiences with management, poor project organization, and communication issues.
- The hiring process can be challenging, with some candidates reporting negative interview experiences.
- There are concerns about job security and advancement opportunities within the company.
- Cologuard is not recommended for individuals with a history of polyps, family history of colon cancer, or high-risk conditions.
Based on reviews from: Reddit, Indeed.com, Facebook, Gastroenterology Consultants of San Antonio, YouTube, Jobstore.com, Capterra, G2
Last updated: 2026-08-25
Videos
News, demos, and interviews about Exact Sciences.
Videos load interactively. If none appear, search YouTube for Exact Sciences →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Exact Sciences.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]